Literature DB >> 3221303

Lymphatic transport of recombinant human tumor necrosis factor in rats.

K Kojima1, T Takahashi, Y Nakanishi.   

Abstract

The lymphatic transport of recombinant human tumor necrosis factor (rHu-TNF) was investigated after its administration via various routes in anesthetized rats. After intravenous (i.v.) administration, the level of rHu-TNF in the lymph reached a peak at 2 h, and thereafter decreased exponentially in a pattern similar to that of the elimination from plasma. Intramuscular (i.m.) and subcutaneous (s.c.) administrations resulted in low levels of rHu-TNF both in the plasma and in the lymph. On the other hand, intraperitoneal (i.p.), intra-stomach wall (s.w.) and intra-gut wall (g.w.) administrations gave high lymph levels of rHu-TNF. After the s.w., g.w. and i.p. administrations, the ratios of rHu-TNF recovered from the thoracic duct to the cumulative amount estimated from the rHu-TNF concentration in plasma were about 25, 32 and 8 times higher than in the case of i.v. administration, respectively. These results suggest that the routes of local administration of rHu-TNF such as s.w., g.w. and i.p. may be highly effective for the treatment of lymphatic metastasis of cancer.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3221303     DOI: 10.1248/bpb1978.11.700

Source DB:  PubMed          Journal:  J Pharmacobiodyn        ISSN: 0386-846X


  7 in total

Review 1.  Mechanistic determinants of biotherapeutics absorption following SC administration.

Authors:  Wolfgang F Richter; Suraj G Bhansali; Marilyn E Morris
Journal:  AAPS J       Date:  2012-05-23       Impact factor: 4.009

2.  Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.

Authors:  Yulia Vugmeyster; Xin Xu; Frank-Peter Theil; Leslie A Khawli; Michael W Leach
Journal:  World J Biol Chem       Date:  2012-04-26

3.  Pharmacokinetics, lymph node uptake, and mechanistic PK model of near-infrared dye-labeled bevacizumab after IV and SC administration in mice.

Authors:  Fang Wu; Mitalee Tamhane; Marilyn E Morris
Journal:  AAPS J       Date:  2012-03-06       Impact factor: 4.009

4.  Interrelationships between Infliximab and Recombinant Tumor Necrosis Factor-α in Plasma Using Minimal Physiologically Based Pharmacokinetic Models.

Authors:  Xi Chen; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Drug Metab Dispos       Date:  2017-04-14       Impact factor: 3.922

5.  Characterization and Interspecies Scaling of rhTNF-α Pharmacokinetics with Minimal Physiologically Based Pharmacokinetic Models.

Authors:  Xi Chen; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Drug Metab Dispos       Date:  2017-04-14       Impact factor: 3.922

Review 6.  Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.

Authors:  Michael R Turner; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2018-01-11       Impact factor: 3.534

Review 7.  Understanding Inter-Individual Variability in Monoclonal Antibody Disposition.

Authors:  Veena A Thomas; Joseph P Balthasar
Journal:  Antibodies (Basel)       Date:  2019-12-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.